Novartis has terminated a mid-stage trial of Fabhalta, its oral factor B inhibitor iptacopan, in lupus nephritis, citing strategic considerations in a federal clinical trials database entry.
Why it matters: The termination removes one expansion path for Fabhalta beyond its approved blood and kidney indications, though no safety or efficacy reason was reported in the material available.
Data as of Friday, October 16, 2026, 12:42 ET. Single sourced to Endpoints News. The article is paywalled; this item is based on the publisher's visible summary, opened in the browser, and is graded C for that limitation. No trial identifier or patient numbers were visible.
Novartis has terminated a mid-stage trial of Fabhalta (iptacopan) in lupus nephritis, according to Endpoints News, which cited a federal clinical trials database entry giving strategic considerations as the reason. No further Novartis statement was visible in the material available.
Fabhalta is an oral factor B inhibitor already marketed for other indications. The report did not state any implication for those uses, and no safety or efficacy finding was reported.